MYGN · Myriad Genetics Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $200.40M | - | $205.70M | $213.10M | $195.90M | - | $213.30M | $211.50M | $202.20M | - |
| Cost of Revenue | $62.80M | - | $61.90M | $61.30M | $61.70M | - | $63.50M | $64.40M | $64.60M | - |
| Gross Profit | $137.60M | - | $149.80M | $147.10M | $137.60M | - | $149.80M | $147.10M | $137.60M | - |
| R&D | $27.10M | - | $28.20M | $25.60M | $27.50M | - | $28.50M | $27.10M | $24.90M | - |
| SG&A | $62.20M | - | $69.20M | $72.10M | $71.20M | - | $139.10M | $144.90M | $140.60M | - |
| Total Operating Expenses | $168.30M | - | $169.80M | $183.60M | $165.50M | - | $233.30M | $248.00M | $230.10M | - |
| D&A | $12.50M | - | $4.80M | $4.90M | $14.40M | - | $4.80M | $4.60M | $15.70M | - |
| Operating Income | ($30.70M) | - | ($23.30M) | ($329.20M) | ($29.00M) | - | ($20.00M) | ($36.50M) | ($27.90M) | - |
| Interest Expense | $4.10M | - | $3.80M | $1.50M | $500.0K | - | $1.00M | $800.0K | $500.0K | - |
| Income Tax | $0 | - | $1.20M | ($100.0K) | ($29.30M) | - | $900.0K | ($500.0K) | $100.0K | - |
| Net Income | ($34.10M) | - | ($27.40M) | ($330.50M) | ($100.0K) | - | ($22.10M) | ($36.70M) | ($26.00M) | - |
| EPS - Basic | ($0.36) | - | ($0.29) | ($3.57) | $0.00 | - | ($0.24) | ($0.41) | ($0.29) | - |
| EPS - Diluted | ($0.36) | - | ($0.29) | ($3.57) | $0.00 | - | ($0.24) | ($0.41) | ($0.29) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $124.40M | $149.60M | $145.40M | $74.40M | $91.80M | $102.40M | $99.90M | $92.40M | $96.90M | $132.10M |
| Accounts Receivable | $123.80M | $115.30M | $118.00M | $137.00M | $120.40M | $121.20M | $125.70M | $117.80M | $118.10M | $114.30M |
| Inventory | $27.90M | $30.60M | $31.60M | $28.70M | $28.30M | $27.50M | $26.20M | $26.10M | $24.60M | $22.00M |
| Accounts Payable | $32.60M | $30.00M | $31.80M | $30.90M | $28.10M | $32.30M | $29.60M | $33.30M | $33.10M | $25.80M |
| Current Assets | $312.80M | $332.60M | $344.80M | $284.30M | $287.20M | $298.00M | $293.20M | $291.60M | $290.30M | $313.60M |
| Total Assets | $673.70M | $706.60M | $728.10M | $677.30M | $1.01B | $1.03B | $1.08B | $1.09B | $1.11B | $1.15B |
| Current Liabilities | $130.20M | $133.80M | $148.00M | $199.90M | $151.10M | $164.10M | $154.30M | $148.90M | $146.10M | $155.90M |
| Long-term Debt | $120.30M | $119.90M | $119.50M | $0 | $59.30M | $39.60M | $39.00M | $38.80M | $38.70M | $38.50M |
| Total Liabilities | $336.30M | $338.60M | $355.30M | $289.20M | $301.20M | $326.50M | $349.60M | $344.60M | $350.50M | $363.30M |
| Stockholders' Equity | $337.40M | $368.00M | $372.80M | $388.10M | $704.90M | $701.10M | $731.70M | $740.50M | $760.00M | $783.20M |
| Retained Earnings | ($1.16B) | ($1.12B) | ($1.11B) | ($1.09B) | ($756.90M) | ($756.80M) | ($714.30M) | ($692.20M) | ($655.50M) | ($629.50M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($15.70M) | - | - | - | ($16.30M) | - | - | - | ($18.60M) | - |
| Investing Cash Flow | ($6.50M) | - | - | - | ($8.30M) | - | - | - | ($7.10M) | - |
| Financing Cash Flow | ($3.00M) | - | - | - | $13.60M | - | - | - | ($8.80M) | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 68.7% | - | 72.8% | 69.0% | 70.2% | - | 70.2% | 69.6% | 68.1% | - |
| Operating margin | -15.3% | - | -11.3% | -154.5% | -14.8% | - | -9.4% | -17.3% | -13.8% | - |
| EBITDA margin | -9.1% | - | -9.0% | -152.2% | -7.5% | - | -7.1% | -15.1% | -6.0% | - |
| Net margin | -17.0% | - | -13.3% | -155.1% | -0.1% | - | -10.4% | -17.4% | -12.9% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 13.5% | - | 13.7% | 12.0% | 14.0% | - | 13.4% | 12.8% | 12.3% | - |
| SG&A / Revenue | 31.0% | - | 33.6% | 33.8% | 36.3% | - | 65.2% | 68.5% | 69.5% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -5.1% | - | -3.8% | -48.8% | -0.0% | - | -2.0% | -3.4% | -2.3% | - |
| Return on equity | -10.1% | - | -7.3% | -85.2% | -0.0% | - | -3.0% | -5.0% | -3.4% | - |
| Return on invested capital | -5.3% | - | -3.7% | -67.0% | -3.0% | - | -2.1% | -3.7% | -2.8% | - |
| Liquidity | ||||||||||
| Current ratio | 2.40 | 2.49 | 2.33 | 1.42 | 1.90 | 1.82 | 1.90 | 1.96 | 1.99 | 2.01 |
| Quick ratio | 2.19 | 2.26 | 2.12 | 1.28 | 1.71 | 1.65 | 1.73 | 1.78 | 1.82 | 1.87 |
| Cash ratio | 0.96 | 1.12 | 0.98 | 0.37 | 0.61 | 0.62 | 0.65 | 0.62 | 0.66 | 0.85 |
| Leverage | ||||||||||
| Debt / Equity | 0.36 | 0.33 | 0.32 | 0.00 | 0.08 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 |
| Debt / Assets | 0.18 | 0.17 | 0.16 | 0.00 | 0.06 | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -7.5x | - | -6.1x | -219.5x | -58.0x | - | -20.0x | -45.6x | -55.8x | - |
| Equity multiplier | 2.00 | 1.92 | 1.95 | 1.75 | 1.43 | 1.47 | 1.48 | 1.47 | 1.46 | 1.46 |
| Liabilities / Assets | 0.50 | 0.48 | 0.49 | 0.43 | 0.30 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 |
| Efficiency | ||||||||||
| Asset turnover | 0.30 | - | 0.28 | 0.31 | 0.19 | - | 0.20 | 0.19 | 0.18 | - |
| Inventory turnover | 2.25 | - | 1.96 | 2.14 | 2.18 | - | 2.42 | 2.47 | 2.63 | - |
| Days sales outstanding | 225d | - | 209d | 235d | 224d | - | 215d | 203d | 213d | - |
| Days inventory outstanding | 162d | - | 186d | 171d | 167d | - | 151d | 148d | 139d | - |
| Days payable outstanding | 189d | - | 188d | 184d | 166d | - | 170d | 189d | 187d | - |
| Cash conversion cycle | 198d | - | 208d | 222d | 226d | - | 196d | 162d | 165d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.2x | - | 1.8x | 1.3x | 1.2x | - | 3.4x | 3.0x | 2.5x | - |
| P / S | 2.1x | - | 3.3x | 2.3x | 4.1x | - | 11.7x | 10.5x | 9.5x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 2.3% | - | -3.6% | 0.8% | -3.1% | - | 11.2% | 15.3% | 11.6% | - |
| Revenue CAGR (3y) | 3.4% | - | 9.6% | 5.9% | 5.9% | - | 8.4% | 3.7% | 11.7% | - |
| Revenue CAGR (5y) | 6.7% | - | 4.6% | 1.8% | 1.0% | - | -0.3% | -0.5% | -0.0% | - |
| Gross profit growth (YoY) | 0.0% | - | 0.0% | 0.0% | 0.0% | - | 11.5% | 17.0% | 3.3% | - |
| Operating income growth (YoY) | -5.9% | - | -16.5% | -801.9% | -3.9% | - | 66.7% | 67.9% | 46.6% | - |
| Net income growth (YoY) | -34000.0% | - | -24.0% | -800.5% | 99.6% | - | 63.9% | 68.4% | 52.5% | - |
| EPS growth (YoY) | - | - | -20.8% | -770.7% | - | - | 68.0% | 71.1% | 56.7% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -52.1% | -47.5% | -49.1% | -47.6% | -7.2% | -10.5% | 7.1% | 0.7% | -9.0% | -11.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$824.50M totalHereditary Cancer$372.40M · 45.2%
Prenatal$186.30M · 22.6%
Mental Health$144.10M · 17.5%
Tumor Profiling$121.70M · 14.8%
Geographic
$824.50M totalUS$768.00M · 93.1%
Non Us$56.50M · 6.9%
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing MYRIAD GENETICS INC against the 5 most active filers in the same SIC group.
Dividends
$0.00/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Jul 1, 2009 | $1.7500 |
| Jun 15, 2009 | $1.7500 |